drugset / Trial / NCT04258826

A Study to Evaluate LY3154207 on the Brain of Healthy Participants

NCT04258826

Phase 1 Completed 16 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.

Timeline

Start
2021-01-15
Primary completion
2022-01-28
Completion
2022-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Mevidalen Small molecule Oral

Indications

No indication recorded.